STADA - Generics with “value for money”
Generics contributed 73.2% to sales in 2006 (previous year: 74.3%) and represents STADA’s largest core segment by far. In 2006, sales in the generics core segment rose by 20% to EUR 911.2 million (2005: EUR 759.3 million1)). A part of this growth is based on the acquisition of the Serbian Hemofarm, whose product portfolio includes approx. 75% of generics. Group sales in the generics core segment rose by 32% to EUR 821.5 million in the first nine months of 2007 (1-9/2006: EUR 624.7 million2)).
Generics are drugs which, after expiration of the patent or other relevant commercial property rights, are offered in the same quality but for lower prices than products of an initial supplier having the same active ingredient. This means generics are typical “multisource products” with active ingredients that any supplier can readily procure.
Generics have a high structural growth potential. The basis for this on the one hand is the pressure to contain costs in numerous national health care markets because generics allow, in many indication areas, a low-cost medical therapy without quality cutbacks. On the other hand, the continuous expiration of patents or other commercial property rights ensures a constant automatic expansion of market potential available for generic competition. Historical data as well as forecast market data demonstrate the growth momentum of generics which is characterized by these two sustainable market trends.
There is no question that spending restraints in the different national health care systems form the basis for the long-term growth potential of generics suppliers. However, due to the associated low price expectations, the generics market is a very price-sensitive segment. Reactions to lasting or temporary challenges occurring in individual national markets due to regulation and /or competition must be specifically and flexibly targeted at the individual national market.
In Germany, the Group's generic drugs are marketed by the Group subsidiary STADApharm GmbH, STADA Medical GmbH, ALIUD Pharma GmbH & Co. KG, cell pharm GmbH and Hemofarm GmbH3).
STADA´s sales network outside of Germany consists the following sales companies in Europe: Austria, Belgium, Bosnia, the Czech Republic, Denmark, Finland, France, Ireland, Italy, Lithuania, Macedonia, Montenegro, the Netherlands, Portugal, Romania, Russia, Serbia, Spain, Sweden, Ukraine and United Kingdom.
Further own sales companies outside of Europe are in: China, Kazakhstan, Vietnam, Philippines and Thailand.
| Contact Details: |
| 5 Cedar Brook Drive |
| Bad Vilbel |
| |
| D-61118 |
| Germany |
| Tel: | +49 6101 603-0 |
| Fax: | +49 6101 603-259 |
| Email: | info@stada.de |
| WWW: | www.stada.de/
|
| |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 928 times since April 2007, the link to the organisation's website has been followed 97 times
Recent Search Terms used to find this page: aliud pharma review | STADA Arzneimittel AG email | thetend | hemopharm stada bad vilbel new building | stada medicin | stada AG | STADA Arzneimittel AG ALIUD PHARMA gmbh | product list of stada | who is azzalure suuplier | STADA MEDICAL IN IRELAND | .
Search for more companies in Bad Vilbel
Search for more companies in
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
STADA Arzneimittel AG
